PRKDC and cancer: The evidence provided by this review shows that sensitivity to DNA-PKcs inhibitors is correlated with the activity of several signaling pathways, in particular the PI3K (Phosphoinositide 3-kinase)/AKT/mTOR pathway and epithelial/mesenchymal state in cancer.